Skin cancers are now more common than all other cancers combined. At the Center for Cutaneous Oncology, we focus exclusively on skin cancer treatment and research. Our specialists work together, and with you, to create a treatment plan that supports your medical, nutritional, and emotional needs.
At the Center for Cutaneous Oncology, we believe that each case of skin cancer is as unique as the individual facing the diagnosis. Experts from a wide variety of medical fields are here to evaluate and treat your particular skin cancer, no matter how rare or complex.
As a patient, you are at the center of a dedicated team that works closely together. You'll have access to some of the world's leading skin cancer specialists, including dermatologic oncologists, dermatopathologists, medical oncologists, surgical oncologists, radiation oncologists, radiologists, and other specialists. Together, your team will develop an individualized treatment plan tailored to the stage and particular features of your disease, any general health concerns, and lifestyle considerations.
The experts at the Center for Cutaneous Oncology are dedicated to cancer research, from clinical investigation to basic science, exploring and understanding the fundamental causes of skin cancers.
Skin cancers are more common than all other cancers combined, and, collectively, their incidence is rising faster than that of any other cancer. Our Cutaneous Lymphoma, Cutaneous Carcinoma, and Oncologic Dermatology Programs provide highly specialized care for all types of non-melanoma skin cancer, including:
We also treat cutaneous complications of therapy for cancers in general, including:
Immunosuppressed patients have an elevated risk of skin cancer, a factor particularly relevant for light-skinned patients who have experienced multiple sunburns in their lifetime. The ISC clinic specializes in the prevention and treatment of skin cancer in patients who are immunosuppressed due to certain diseases or immune-suppressing medications.
The ISC Clinic provides information on sun protection and avoidance to help patients decrease their risk of skin cancer, and provide topical or oral treatments when appropriate to slow down or reverse sun damage. With proactive treatments and monitoring offered at the ISC, even patients who have had multiple cancers can be effectively treated and have a marked decrease in the number of new cancers they develop.
As a patient in the Center for Cutaneous Oncology, you will be cared for by a comprehensive team that combines leading experts with the latest technological and research advances. Our team works together to create personalized treatment that supports all your medical, nutritional, and emotional needs.
You have access to:
Other therapies that may be used in your treatment include:
Treatment of CTCL is dependant upon the stage of disease. CTCL limited to the skin can be treated with a skin-directed therapy, while CTCL that also involves blood, lymph nodes, or other organs requires systemic therapy.
Treatment of advanced CTCL is highly specialized. We offer a variety of systemic therapies for CTCL patients with advanced stage disease including:
Cutaneous B cell lymphomas are less common than CTCL. The treatment of most primary CBCLs is very different from B cell lymphoma that involves the lymph nodes. How we treat the disease also depends on the specific cell type features, the extent of skin involvement, and whether or not the blood and lymph nodes are involved.
Recommended treatments may include a variety of therapies, including ultraviolet light therapy, biological response modifier therapy, electron beam radiation therapy, oral or intravenous chemotherapy.
Systemic therapies for cutaneous B cell lymphomas that involve skin and lymph nodes or other organs are similar to those for B cell lymphomas in general. The Center works closely with the Lymphoma Program to make sure our patients receive the appropriate treatment for their disease.
The Cutaneous Lymphoma program also treats very rare diseases of the hematopoietic system involving skin, including Natural Killer Cell Lymphomas (NK lymphomas), NK/T cell lymphomas, Langerhans Cell Histiocytosis, and Leukemia Cutis.
Merkel cell carcinoma is a rare and aggressive cutaneous neuroendocrine carcinoma. Our team of experts in dermatologic oncology, surgical oncology, radiation oncology, and medical oncology will work to develop a treatment plan depending on the stage of Merkel cell carcinoma. Your evaluation and treatment may include:
Basal cell carcinoma is the most common form of cancer, with about one million new cases estimated in the U.S. each year. When detected early, it can be easily treated; however, if not addressed quickly and definitively, it can be difficult to eliminate. Basal cell carcinoma on the face is typically treated with Mohs micrographic surgery, an approach that provides the highest cure rate, lowest recurrence, and the best cosmetic result.
Squamous cell carcinoma is the second most common form of skin cancer, with more than 250,000 new cases per year estimated in the United States. Most cases of squamous cell carcinoma can be cured when identified early.
Squamous cell carcinoma is usually treated with surgery. Mohs surgery is used if the tumors are located on the face, are larger than a nickel, or have other aggressive features. Surgical oncologists treat localized metastasis, and these patients often require postoperative radiation and chemotherapy.
The Center for Cutaneous Oncology also treats rare adnexal tumors of eccrine, apocrine, sebaceous and hair follicle origin. Other extremely rare cutaneous cancers seen at the Center include:
Increasingly, centers are moving towards allogeneic stem cell transplantation in selected CTCL patients with advanced, refractory, or aggressive disease, with the goal of long term remission and cure. The Center for Cutaneous Oncology works closely with the Bone Marrow Transplant team to offer the best possible treatment for all patients.
GVHD occurs as a result of allogeneic hematopoietic stem cell therapy for leukemias and lymphomas, when white blood cells from the donor (the graft) identify cells in the patient's body (the host) as foreign and attack them. Although less common, it can also occur after solid organ transplantation, particularly after liver and small bowel transplantation. Skin is the most common target of involvement in GVHD.
The goal in treating GVHD is to treat the disease without impairing graft-versus-leukemia (or lymphoma) effects. Through our coordinated team, we can choose among various oral pharmacologic therapies, infusion medications, and extracorporeal photopheresis.
Oral and infusion medications such as mycophenolate, tacrolimus, sirolimus and rituximab, among others, are used to treat and prevent disease progression. Physical therapy helps treatment and prevention of joint problems and skin tears. Wound care is central to our therapeutic work, which aims at preventing infection and inducing full wound closure.
Finally, our center is also able to assist with the treatment of drug reactions and other cancer-related skin diseases in patients who also have GVHD.
Though the Center focuses on adult patients, a clinic is also offered for pediatric patients in conjunction with the Jimmy Fund Clinic.
Developed in the 1940s by Dr. Frederic Mohs, Mohs micrographic surgery is an outpatient procedure that involves surgically removing the visible tumor, along with a thin layer of normal-appearing tissue around and beneath the tumor. This tissue is then frozen and examined under a microscope. If cancer is seen at the edges or under the surface of the removed tissue, additional tissue is removed from the patient, but only in the area where cancer remains.
Mohs is primarily used to treat basal cell carcinoma and squamous cell carcinoma. It has become a standard treatment for tumors on the face, hands, and lower legs, where it is important to preserve normal skin, or where healing is difficult.
Although no treatment is guaranteed, the success rate of Mohs micrographic surgery is very high — 98 percent for most cases — even if other forms of treatment have failed. This is due to the microscopic examination of nearly 100 percent of the cut surgical surface, which minimizes the chance that cancer cells are left behind during surgery.
The rapid and precise examination of the removed skin reduces guesswork, which means as little healthy tissue as possible is removed. As a result, Mohs surgery tends to minimize scarring.
Dana-Farber Cancer Institute and Brigham and Women's Hospital are teaching affiliates of Harvard Medical School, where our physicians and researchers are faculty members. Our clinicians focus exclusively on skin cancers. They combine their expertise in dermatologic oncology, medical oncology, surgical oncology, radiation oncology, and dermatopathology to create the most effective treatment plans specific to your needs.
Thomas Kupper, MD, Disease Center LeaderAndrew Werchniak, MD, Clinical Director
Allison Goddard, MDThomas Kupper, MDNicole LeBoeuf, MDStephanie Liu, MDManisha Thakuria, MD
Chrysalyne Schmults, MD
David C. Fisher, MDCorey S. Cutler, MD, MPH, FRCPC
Phillip Devlin, MDAndrea Ng, MD
Scott Granter, MDGeorge Murphy, MD
Marianne Tawa, RN, MSN, ANP
Jennifer Elliott, PA-C
Suzanne MacRae, RN, BS, MPH
The Center for Cutaneous Oncology has been associated with the National Cancer Institute-supported Specialized Program of Research Excellence (SPORE) since 2001. The Harvard Skin Cancer SPORE is the first of its kind in the U.S. designed to speed laboratory insights directly to patient care. Many of our physicians who treat patients with skin cancer are involved in the research associated with the SPORE grant.
The Center for Cutaneous Oncology has a variety of clinical trial options available. You can enroll in our blood, tissue, and database collection studies for cutaneous T cell lymphoma (CTCL) or Merkel cell carcinoma (MCC). The goal of this research is to understand the genetic and biologic factors that may contribute to the development of CTCL and MCC, and to better understand why tumors develop.
The Center for Cutaneous Oncology has a variety of targeted therapeutic clinical trials for the treatment of CTCL, MCC and basal cell carcinoma (BCC).
For more information regarding enrollment and eligibility, please call 617-632-6571.
If you have never been seen before at Dana-Farber/Brigham and Women's Cancer Center, please call 877-442-3324 or use this online form to make an appointment. You may also call us directly at 617-632-6171.
For other patient questions or information, call us at 617-632-6571.
Referring physicians: 877-441-3324
Mohs Micrographic Surgery CenterPhone: 617-983-4626Fax: 617-983-4504
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: